FARNBOROUGH, England--(BUSINESS WIRE)--July 13, 2006--GE-Aviation expects revenues to grow in 2006 to a record $12.8 billion.
The 2006 growth follows a strong 2005 financial performance, when revenues grew to $11.9 billion, up from $11.1 billion in 2004.
Meanwhile, GE-Aviation continues its aggressive technology development program, investing more than $1 billion annually in research and development for new engines, as well as upgrades for current production engines.
PISCATAWAY, N.J.--(BUSINESS WIRE)--July 10, 2006--The Translational Genomics Research Institute (TGen) and GE Healthcare (NYSE:GE) announced today a strategic alliance designed to apply advanced cellular genomics technologies and strategies to improve and accelerate the discovery and development of new drugs. This research collaboration will support the mutual goals of translating basic genomic research into early health solutions for some of the most urgent problems facing healthcare today.
SINGAPORE--(BUSINESS WIRE)--June 23, 2006--Fonterra, a global dairy business and expert in nutritional dairy products, and GE Healthcare's Lunar business, the industry leader in bone assessment technologies, today announced a partnership to tackle the growing global health problem of osteoporosis head-on using Fonterra's ANLENE(TM) bone health products and GE Healthcare's bone mineral density technology.
State-of-the-art Fitness Center to Provide Employees and Spouses with Space to Get/Stay Fit
LAWRENCE PARK, Pa. (June 13, 2006) -- General Electric today announced the completion of a new, 8,000 square foot Health & Wellness Center for use by GE employees, spouses and retirees. The new center, located at the heart of GE Transportation's plant, is in a 94-year-old building that was renovated into a state-of-the-art facility over the past 6 months.
--(BUSINESS WIRE)--The clinical trial, sponsored by GE Healthcare, will test a new imaging agent for cancer detection on more than two-dozen breast cancer patients. This research will track the process of angiogenesis, which is the growth of new blood vessels in the body. This experimental contrast agent could help doctors monitor new vessel production, and identify a tumor's exact dimensions. If the trial is successful, researchers say the results could be "groundbreaking" for cancer patients.
CHALFONT ST. GILES, England--(BUSINESS WIRE)--June 7, 2006--GE Healthcare (NYSE:GE):
New York Blood Center's National Cord Blood Program
is the first to automate the processing, cryopreservation and
storage of cord blood stem cell units to achieve the
highest standards of quality and consistency
GE is preparing to ship its 1,000th Evolution® Series locomotive.
GE is preparing to ship its 1,000th Evolution® Series locomotive.
Click here to listen to the podcast (MP3)
Investor Contact Information
CHALFONT ST GILES, England--(BUSINESS WIRE)--June 5, 2006--GE Healthcare, a division of the General Electric Company (NYSE:GE), announced today that it has initiated a first-in-man clinical study designed to validate information provided by a molecular imaging agent in evaluating the extent and nature of cancer. Specifically, this proprietary positron emission tomography (PET) agent has a biological mechanism to track the process of angiogenesis, the formation of new blood vessels in the body.
